AI‑drug developer Insilico Medicine filed for a Hong Kong IPO aiming to raise roughly HK$2.27 billion (about $292 million) to fund clinical development and expand investments in generative AI and automated labs. Management said proceeds will support the clinical pipeline, early‑stage candidate R&D, and AI model development. The float follows growing investor interest in AI‑enabled biotech and comes as the company eyes global expansion of its discovery platforms. Insilico plans to deploy capital to move assets toward the clinic while bolstering its computational and lab automation capabilities. A successful IPO would deepen private‑public capital flows into generative AI for drug discovery and provide liquidity for a sector still balancing long development timelines with powerful computational tools.